These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10730145)

  • 21. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Revision needed of follow-up policy for Barrett's esophagus].
    Giard RW; Coebergh JW; Ouwendijk RJ
    Ned Tijdschr Geneeskd; 2002 Jan; 146(4):150-4. PubMed ID: 11845562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surgical therapy for Barrett's esophagus with high-grade dysplasia and early esophageal carcinoma.
    Gilbert S; Jobe BA
    Surg Oncol Clin N Am; 2009 Jul; 18(3):523-31. PubMed ID: 19500741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
    Chatelain D; Fléjou JF
    Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-grade dysplasia in Barrett's esophagus has a high risk of progression.
    Lim CH; Treanor D; Dixon MF; Axon AT
    Endoscopy; 2007 Jul; 39(7):581-7. PubMed ID: 17611911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New advances in the diagnosis and treatment of early onset dysplasia and adenocarcinoma in Barrett's oesophagus].
    Pera M; Grande L; Iglesias M; Ramón JM; Conio M
    Cir Esp; 2009 Jun; 85(6):331-40. PubMed ID: 19463990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer.
    Fountoulakis A; Zafirellis KD; Dolan K; Dexter SP; Martin IG; Sue-Ling HM
    Br J Surg; 2004 Aug; 91(8):997-1003. PubMed ID: 15286961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Esophageal polypoid dysplasia of gastric foveolar phenotype with focal intramucosal carcinoma associated with Barrett's esophagus.
    Asthana N; Mandich D; Ligato S
    Am J Surg Pathol; 2008 Oct; 32(10):1581-5. PubMed ID: 18724240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus.
    Incarbone R; Bonavina L; Saino G; Bona D; Peracchia A
    Surg Endosc; 2002 Feb; 16(2):263-6. PubMed ID: 11967675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Barrett carcinoma--diagnosis, screening, surveillance, endoscopic treatment, prevention].
    Peitz U; Malfertheiner P
    Z Gastroenterol; 2007 Dec; 45(12):1264-72. PubMed ID: 18080229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
    Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors for squamous re-epithelialization of Barrett's esophagus after endoscopic biopsy.
    Amano Y; Kushiyama Y; Yuki T; Takahashi Y; Chinuki D; Ishimura N; Furuta K; Ishihara S; Adachi K; Maruyama R; Kinoshita Y
    J Gastroenterol Hepatol; 2007 Jun; 22(6):901-7. PubMed ID: 17565646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined oesophageal adenocarcinoma and carcinoid in Barrett's oesophagitis: potential role of enterochromaffin-like cells in oesophageal malignancy.
    Cary NR; Barron DJ; McGoldrick JP; Wells FC
    Thorax; 1993 Apr; 48(4):404-5. PubMed ID: 8511743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Risk estimation in Barrett's esophagus: biomolecular marker and histopathologic classification].
    Walch A; Schmitt-Gräff A; Stein H; Werner M
    Zentralbl Chir; 2002 Dec; 127(12):1073-7. PubMed ID: 12529823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
    Cooper BT; Chapman W; Neumann CS; Gearty JC
    Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curative treatment for high-grade intraepithelial neoplasia in Barrett's esophagus.
    Behrens A; May A; Gossner L; Günter E; Pech O; Vieth M; Stolte M; Seitz G; Ell C
    Endoscopy; 2005 Oct; 37(10):999-1005. PubMed ID: 16189774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Barrett's esophagus and medications that relax the lower esophageal sphincter.
    Corley DA; Levin TR; Habel LA; Buffler PA
    Am J Gastroenterol; 2006 May; 101(5):937-44. PubMed ID: 16573773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Carcinoid tumor of the esophagus. A rare differential diagnosis in submucosal esophageal tumor].
    Höring E; Egner E; von Gaisberg U; Kieninger G
    Z Gastroenterol; 1990 Jan; 28(1):10-3. PubMed ID: 2316264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
    Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
    Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A surveillance programme for Barrett's oesophagus in a UK general hospital.
    Olithselvan A; Gorard DA; McIntyre AS
    Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.